Pharmacologically active microcarriers for endothelial progenitor cell support and survival

Area of Science:

• Biomaterials Science
• Regenerative Medicine
• Cell Biology

Background:

• Endothelial progenitor cell (EPC) therapies show promise for neovascularization but are limited by poor cell viability and retention.
• Scaffolds are needed to improve EPC support and function for enhanced regenerative therapies.

Purpose of the Study:

• To investigate the efficacy of pharmacologically active microcarriers (PAMs) for culturing and supporting human early EPCs (eEPCs).
• To assess the role of fibronectin-coated PAMs (FN-PAMs) and VEGF-A releasing PAMs (FN-VEGF-PAMs) in eEPC adhesion, survival, and function.

Main Methods:

• eEPC adhesion and viability assessed using microscopic evaluation and Alamar blue assay.
• Western blot analysis used to measure phospho-ERK(1/2) and PARP-1 expression for cell survival.
• Proliferative and migratory capacities evaluated using Alamar blue and modified Boyden chamber assays, respectively.

Main Results:

• eEPCs adhered efficiently to empty FN-PAMs within hours.
• FN-VEGF-PAMs significantly enhanced eEPC adhesion, endothelial-like phenotype, and cell survival.
• VEGF-A release from FN-PAMs stimulated in vitro migration and proliferation of human umbilical vein endothelial cells (HUVECs).

Conclusions:

• PAMs effectively support eEPC growth and survival.
• FN-VEGF-PAMs represent a promising scaffold for enhancing EPC-based regenerative therapies.
• These findings support the use of PAMs for stimulating endothelial cell function and neovascularization.